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mation in human diabetic nephropathy.
Background. The molecular mechanisms of renal injury in
diabetic nephropathy (DN) are not completely understood, al-
though inflammatory cells play a key role. The renin-angioten-
sin system (RAS) is involved in kidney damage; however, few
studies have examined the localization of RAS components in
human DN. Our aim was to investigate in renal biopsies the
expression of RAS and their correlation with proinflammatory
parameters and renal injury.
Methods. The biopsies from 10 patients with type 2 diabetes
mellitus and overt nephropathy were studied for the expression
of RAS components by immunohistochemistry (IH). In addi-
tion, by Southwestern histochemistry we studied the in situ de-
tection of the activated nuclear factor kappa B (NFB), and
by IH and/or in situ hybridization (ISH), the expression of mono-
cyte chemoattractant protein-1 (MCP-1) and regulated upon
activation, normal T cell expressed and secreted (RANTES),
whose genes are regulated by NFB.
Results. Angiotensin-converting enzyme (ACE) immuno-
staining was elevated in tubular cells and appeared in interstitial
cells. Elevated levels of angiotensin II (Ang II) immunostaining
were observed in tubular and infiltrating interstitial cells. There
was also a down-regulation of AT1 and up-regulation of AT2 re-
ceptors. An activation of NFB and a marked up-regulation
of NFB-dependent chemokines mainly in tubular cells was ob-
served. Elevated levels of NFB, chemokines, and Ang II in
tubules were correlated with proteinuria and interstitial cell
infiltration.
Conclusions. Our results show that in human DN, RAS com-
ponents are modified in renal compartments, showing elevated
local Ang II production, activation of tubular cells, and induc-
tion of proinflammatory parameters. These data suggest that
Ang II contributes to the renal inflammatory process, and may
explain the molecular mechanisms of the beneficial effect of
RAS blockade.
Diabetic nephropathy (DN) is the most common hu-
man renal disease in the Western world, although its
pathogenesis is not completely understood. Despite the
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fact that this condition is not considered an inflammatory
disease, the presence of interstitial mononuclear cells is
widely recognized. The nuclear factor kappa B (NFB)
is a transcription factor that regulates the gene expres-
sion of several proinflammatory mediators, including cyto-
kines, adhesion molecules, and chemokines [1–3]. Among
these genes, monocyte chemoattractant protein-1 (MCP-1)
and regulated on activation normal T-cells expressed and
secreted chemokine (RANTES) play important roles in
the recruitment of inflammatory cells [3–5]. Activation
of renal NFB has been described in human and expe-
rimental nephritis [3, 6–8]. In human proteinuric non-
diabetic renal disease, we have shown that tubular over-
activation of NFB, and simultaneous up-regulation of
certain proinflammatory and profibrogenic genes, are
markers of progressive renal disease [9]. The beneficial
effects of NFB inhibition have recently been tested in
experimental renal immune diseases [10].
Activation of local renin-angiotensin system (RAS)
seems to be involved in the progression of kidney dam-
age, including DN. Studies in experimental animal mod-
els of DN have demonstrated up-regulation of RAS com-
ponents and beneficial effect of RAS blockade [11]. In
human DN, treatment with angiotensin-converting en-
zyme (ACE) inhibitors and AT1 antagonists retarded dis-
ease progression. Results from large clinical trials have
recently confirmed the beneficial effects of these drugs
in DN [12–14]. Although some evidence suggests activa-
tion of intrarenal RAS in diabetes [11], the localization
of renal expression of RAS components, as well as the
source of intrarenal angiotensin II (Ang II) and its po-
tential relation with inflammation, remains unclear. Ang
II is a cytokine that participates in the inflammatory
response in the kidney through the regulation of NFB
and related genes, such as cytokines, adhesion molecules,
and the chemokines MCP-1 and RANTES [15, 16]. Our
working hypothesis is that elevated intrarenal Ang II
activity may contribute to the inflammatory response
and thereby to the progression of kidney damage in DN.
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METHODS
Human kidney specimens
Kidney samples were obtained by percutaneous renal
biopsy from patients undergoing diagnostic evaluation
at the Division of Nephrology, Austral University, Val-
divia, Chile. Renal biopsies from 10 patients with type 2
diabetes mellitus and overt nephropathy were studied.
None of the patients had good metabolic control. Four
out of 10 patients had proteinuria in the nephrotic range.
None of the patients were being treated with ACE inhibi-
tors or AT1 antagonists at the time of the biopsy, and
none of them had renal vein thrombosis.
Human control kidney specimens (N  5) were taken
from normal portions of renal tissue from patients who
underwent surgery because of localized renal tumors.
Light microscopy, Southwestern histochemistry, in situ
hybridization and immunohistochemistry
Paraffin-embedded sections were treated for each tech-
nique as previously described [9]. Morphology was eval-
uated by hematoxylin and eosin (H&E), periodic acid-
Schiff (PAS), and silver methenamine staining. Masson
staining was used to evaluate the presence of interstitial
fibrosis.
Southwestern histochemistry (SWH) was done as de-
scribed earlier [9]. Controls included absence of probe,
mutant NFB DIG-labeled probe (sense: 5-AGTTGA
GGCTCCTTTCCCAGGC-3), and competition assays
with a 200-fold excess of unlabeled NFB, followed
by incubation with labeled probe. In situ hybridization
(ISH) was performed as described previously [9, 17].
Biotin-labeled human MCP-1 and RANTES probes
were purchased from R&D Systems (Minneapolis, MN,
USA). The specificity of the reaction was confirmed:
(1) by demonstrating the disappearance of hybridization
signal when RNAse (100 ug/mL) (Sigma Chemical Co.,
St. Louis, MO, USA) was added to 0.05 mol/L Tris after
the digestion with proteinase K; (2) with the use of a
sense probe (R&D Systems); (3) with a negative control
(Plasmid DNA) (Dako Corp., Carpinteria, CA, USA);
and (4) without a probe. For immunohistochemistry
(IMH) in paraffin-embedded tissue, the following pri-
mary antibodies were employed: anti-MCP-1 [goat poly-
clonal immunoglobulin G (IgG), AB-279-NA; R&D Sys-
tems)]; anti-RANTES (goat polyclonal, AB-278-NA;
R&D Systems); anti-OPN (mouse monoclonal, MPIIIB10;
Development Studies Hybridoma Bank, Iowa City, IA,
USA); anti-NFB p50 (goat polyclonal IgG, sc-1191;
Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-
NFB p65 (mouse monoclonal, cat 1697838; Boehringer
Mannheim, Mannheim, Germany); anti-Ang II (rabbit
antiserum, IHC 7002; Peninsula Laboratories, San Car-
los, CA, USA), used as described [18]; A rabbit poly-
clonal antibody (A28A9) developed by our group and
raised against a synthetic peptide corresponding to the
last 20 amino acids of the human ACE intracellular car-
boxyl-terminal sequence (peptides 1258–1277, SLHRH
SHGPQFGSEVELRHS) was used to localize immuno-
reactive ACE. The specificity of the antisera has been
well established in Western blots and immunohistochem-
istry [19]. The antibody is directed against an intracellu-
lar domain of the enzyme and therefore recognizes the
enzyme in its native, membrane-bound form at the site
of synthesis, and does not cross-react with the plasma
(circulating) enzyme, which is truncated in this region
during its release into the circulation [19]. Furthermore,
antibodies to AT1 and AT2 (rabbit polyclonal, Santa Cruz),
CD68 (macrophage marker, Dako Corp.), and -smooth
muscle actin (-SMA) were used. Specific biotinylated
secondary antibodies, followed by streptavidin-horse-
radish-peroxidase (HRP) conjugate (Dako Corp.), and
revealed with diaminobenzidine (DAB), were used. For
all staining, controls consisted of replacing the primary
antibody with a nonspecific IgG of the same species.
Cryostat sections (5 m thick) from tissue fragments,
frozen and kept in liquid nitrogen, were also used for
the detection of T lymphocytes CD4 (mouse monoclonal,
MT310; Dako Corp.) and T lymphocytes CD8 (mouse
monoclonal, DK25; Dako Corp.).
Histochemistry quantification
The percentage and intensity of the labeled surface
area was evaluated by using a KS 300 Imaging System
3.0 (Zeiss, Mu¨nchen-Hallbergmoos, Germany). The de-
gree of staining was calculated by the ratio of suitable
binary threshold image and the total field area, integrat-
ing the intensity of the staining in the specific areas.
Performing the readings in this way allows potential dif-
ferences in the amount of total tissue examined to be
avoided. For each sample, a mean value was obtained
by analysis of 20 different fields (20), excluding glo-
meruli and vessels. Quantification was done twice in a
blinded manner and the interassay variations were not
significant. The staining score is expressed as density/
mm2. This form of analysis, used to quantify immunohis-
tochemical assays, has been validated in previous publi-
cations by our group [9].
Interstitial cell infiltration and fibrosis were classified
into four groups according to their extent and the pres-
ence of tubular atrophy and degeneration: (1) normal;
(2) involvement up to 25%; (3) 26 to 50%; and (4)
extensive damage involving more than 50% of the cortex.
Interstitial fibrosis was defined by the presence of inter-
stitial collagen determined by Masson technique. Stain-
ing for -SMA was particularly prominent in areas of fi-
brosis around atrophic tubules, defining vascular smooth
muscle cells, activated mesangial cells, and interstitial
myofibroblasts.
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Table 1. Clinical data and staining score for NFB of patients with diabetic nephropathy
Serum creatinine Proteinuria MAP
Case Sex Age mg/dL g/day mm Hg NFB
1 F 45 0.8 3.5 93 3361
2 F 40 1.6 3.5 110 4468
3 F 42 0.9 3.5 103 6080
4 F 51 2.3 3.5 120 9851
5 M 54 1.4 3.5 120 8694
6 F 55 1.4 3.5 123 12408
7 M 55 1.5 3.5 140 980
8 F 56 1.7 3.5 133 14153
9 F 60 2.1 3.5 120 4676
10 F 62 2.0 3.5 115 4493
Mean 52	7 1.57	0.48 118	14 6916	1332
Abbreviations are: MAP, mean arterial pressure; NFB, nuclear factor kappa B. Staining score is expressed as density/mm2.
Statistical analysis
Statistical analyses were performed with the GraphPad
Instat and GraphPad Software (San Diego, CA, USA).
Results of the clinical data are expressed as mean 	 SD.
The intensity score and distribution of staining in the
different techniques employed (SWH, IMH, and ISH)
are expressed as the mean 	 SEM. Spearman’s correla-
tion was used to correlate the tubular NFB activation
with the tubular MCP-1 and RANTES over-expression.
Fisher’s test was used when appropriate. A P value of
0.05 was considered significant.
RESULTS
Clinical data
Table 1 summarizes the clinical data for each patient
studied and the staining score of renal NFB activation
by SWH. Eight out of 10 patients were female, with a
mean age of 52 	 7 years. Renal function deterioration
was present in five out of 10 patients, with a serum cre-
atinine over 1.5 mg/dL, and four patients (cases 3 to 6)
had nephrotic syndrome with proteinuria over 3.5 g/day.
A mean arterial pressure (MAP) over 110 mmHg was
present in eight out of 10 patients.
Local RAS is activated in DN
In normal kidneys, ACE immunostaining was only
found in the brush border membrane of tubular cells. In
samples from DN patients, a marked increase in ACE
staining in this region was observed. In addition, a posi-
tive staining for ACE appeared in interstitial cells, mainly
in -actin positive cells (Fig. 1). We further determined
whether local Ang II production was observed in DN. In
the normal kidney, Ang II immunostaining was weakly
expressed, while in DN there was a remarkable increase
in Ang II production in tubular and interstitial infiltrating
cells (Fig. 1). AT1 receptor expression was lower (423 	
82 density/mm2) than AT2 receptor expression (1061 	
221 density/ mm2) in the diabetic kidneys.
NFB is activated in patients with DN
Activated NFB was observed in the kidneys of all
patients studied (Table 1), in comparison with the ab-
sence in normal control kidneys (not shown). There was
a significant association between the magnitude of pro-
teinuria and the staining score for NFB (mean, 6916 	
1332 density/ mm2; P  0.05). Patients with proteinuria
3.5 g/day had significantly higher (P  0.05) NFB
staining score (9258 	 1313) than patients with protein-
uria3.5 g/day (5355 	 1848) . Active NFB complexes
were mainly detected in cortical tubular epithelial cells
and, in a sparse manner, in some glomerular cells, mainly
podocytes (Fig. 2A). Some nuclei of parietal and endo-
thelial cells were also positive for activated NFB. This
transcription factor consists of a heterodimer of p65 and
p50 subunits [1] that were mainly detected in tubular
epithelial cells (cytoplasm and nuclei), without significant
differences between the samples studied (not shown).
Proinflammatory chemokines are up-regulated in DN
In kidneys of DN patients, mRNA expression of the
chemokines MCP-1 (mean, 19,401 	 4318 density/mm2)
and RANTES (mean, 11,914 	 3063 density/mm2) was
mainly detected in tubular epithelial cells (Fig. 2 D and F),
while no mRNA expression was found in control kid-
neys. Similar results were noted in the protein expres-
sion of these chemokines (MCP-1 mean, 1628 	 236;
RANTES, 1215	 268 density/mm2), with a major immu-
nostaining in kidneys with progressive disease, and with
a pattern similar to that observed for their respective
mRNAs (Fig. 2). A marked correlation was found be-
tween gene and protein expression and localization of
both chemokines in the same tubular cells. In addition,
in some DN patients, mild glomerular staining for MCP-1
and RANTES was noted both at mRNA and protein
levels. Moreover, we studied the expression of osteopon-
tin protein (OPN), and this chemokine was mainly de-
tected in tubular epithelial cells of DN patients, with a
similar pattern to that of MCP-1 and RANTES (Fig. 2B).
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Fig. 1. Expression of components of the renin-angiotensin system. Shown
are serial sections of one representative case of diabetes, and one normal
kidney section. In contrast to that observed in the normal kidney, in
which angiotensin-converting enzyme (ACE) was weakly expressed in
the brush border of proximal tubules, a marked up-regulation was noted
in some tubules, and ACE neoinduction appeared in interstitial cells,
mainly -actin positive cells. Angiotensin II (Ang II) immunostaining
was detected in tubular and interstitial infiltrating cells. In comparison
with the widespread distribution of AT1 and AT2 receptors in normal
kidney, in diabetic nephropathy (DN) the staining score for AT1 was
significantly decreased as compared with the AT2 receptor. Magnifica-
tion 200 and 400 normal kidney vs. diabetic kidney, respectively.
In the whole population of patients, the staining score
for MCP-1 and RANTES was significantly correlated
with that for NFB tubular activation (r  0.7; P 
0.01). As noted in serial sections, the same tubular cells
expressed activated NFB in the nuclei and MCP-1 and
RANTES in the cytoplasm (Fig. 2).
Interstitial inflammatory cells are detected in DN
The composition of the inflammatory cell infiltration
was further examined by immunohistochemistry with a
specific anti-monocyte/macrophage CD68, anti-lympho-
cyte CD4, anti-lymphocyte CD8, and anti--smooth mus-
cle actin (interstitial myofibroblasts). As the interstitial
cell infiltration was found in almost all cases, a great
Fig. 2. Activated nuclear factor kappa B (NFB) by Southwestern his-
tochemistry, osteopontin (OPN), monocyte chemoattractant protein-1
(MCP-1), and regulated upon activation, normal T cell expressed and
secreted (RANTES) (protein and mRNA) in human diabetic nephropa-
thy. Activated NFB was mainly detected in (A ) tubular epithelial cells
and, to a lesser extent, in some glomerular and interstitial cells. (B )
Osteopontin, (C and D ) MCP-1, (E and F ) RANTES protein, and
mRNA expressions were detected in the same tubular cells. Immunohis-
tochemical staining for (G ) -smooth muscle actin denotes interstitial
myofibroblasts, and (H ) angiotensin-converting enzyme (ACE) neo-
induction appears in interstitial cells. The different techniques were
performed as described in Methods.
number of cells were recognized as macrophages/mono-
cytes, according to the immunostaining for CD68. How-
ever, in cryostat sections, an increased number of CD4

cells, and, to a lesser extent, CD8
 cells were also found
in the interstitium (not shown). Furthermore, positive
staining for interstitial myofibroblasts (-actin–positive
cells) was found, particularly in areas of fibrosis (Fig. 2G).
In these patients there was a significant association be-
tween the interstitial cell infiltration and fibrosis and the
staining score for NFB (P  0.05, Fisher test).
Association of renal RAS components and
inflammatory parameters in DN
In serial sections of different cases, the ACE over-
expression and neoinduction were coincidental with the
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tubular activation of NFB, MCP-1, and osteopontin, as
well as with the interstitial infiltration and myofibroblast
activation as it is shown in Figures 1 and 2.
DISCUSSION
The tubulointerstitial injury is a major feature of DN
and an important predictor of renal dysfunction. Our
study reveals that renal biopsies from patients with DN
present elevated levels of RAS components (increased
ACE and Ang II expression in tubular and interstitial
cells and AT2 receptors in tubular cells), NFB activa-
tion, and up-regulation of NFB-dependent proinflam-
matory genes (MCP-1, RANTES) were correlated with
the magnitude of proteinuria and the interstitial cell
infiltration.
Activation of NFB has been recently found in the
kidney of streptozotocin-induced diabetes [20] and in
patients with DN [21]. In addition, advanced glycation
end products are able to induce oxidative stress and
activate NFB in cultured mesangial cells and tubular
cells [21, 22]. Insufficient glycemic control, both in type 1
and type 2 diabetes, increases NFB binding activity in
peripheral blood mononuclear cells [23]. NFB activa-
tion was oxidative stress–sensitive and correlated with
the degree of DN [24], thereby strengthening the role of
the oxidative stress and NFB activation in late diabetic
complications [25]. Activated NFB plays an important
role in the up-regulation of MCP-1 and RANTES in
many cell types [3–8]. In our study, NFB activity was
mainly detected in cortical tubular epithelial cells and,
to a lesser extent, in some glomerular cells (mainly podo-
cytes). Some renal interstitial cells, mainly mononuclear
cells, also showed NFB activation. In serial sections we
noted that the same tubular epithelial cells simultane-
ously demonstrated NFB activation and NFB-depen-
dent genes (MCP-1 and RANTES), supporting the con-
cept that this transcription factor is involved in the
expression of these genes. Studies in diabetic rats have
demonstrated an increased glomerular expression of
MCP-1 in the early stages of glomerular injury, coincid-
ing with an infiltration of monocyte/macrophages, and
both findings were suppressed by the Ang II blockade
[26]. In humans, urinary levels of MCP-1 were signifi-
cantly elevated in patients with diabetic nephrotic syn-
drome and advanced tubulointerstitial lesions [27], which
correlated with the extent of proteinuria [28]. MCP-1
production by cultured human mesangial cells is facili-
tated by a diabetic milieu [28], and MCP-1–positive cells
were detected in the interstitium of advanced DN [27].
Our results, obtained in diabetic patients with advanced
glomerular and interstitial lesions, support and extend
those observations, confirming that tubular epithelial
cells are the main source of MCP-1.
The molecular mechanisms involved in NFB activa-
tion and over-expression of related chemokines are not
completely elucidated. At present we cannot discern how
much of the NFB activation is due to the increased
trafficking of proteins in the tubular cells [8, 17, 29, 30]
or to the diabetic condition, per se, or both. High extra-
cellular glucose activates intracellular signaling cascades,
such as NFB, and alters the expression of cytokines
and growth factors, which play a key role in the develop-
ment of renal damage [31]. On the other hand, the mech-
anisms by which proteinuria could cause interstitial in-
flammation and fibrosis are still not fully understood.
The incubation of tubular epithelial cells with albumin,
in concentrations similar to those found in the urine from
patients with nephrotic syndrome, elicited an increment
in the NFB activity [4, 5] that required H2O2 through
a protein kinase C (PKC)-dependent pathway [32]. In
models of renal injury with heavy and sustained protein-
uria, an over-expression of chemokines [29], as well as
of vasoactive peptides (Ang II and endothelin-1) was
noted [33].
The data presented here show another potential mech-
anism that can contribute to the progression of renal
damage in DN—the activation of renal RAS. Studies
using either ACE inhibitors or AT1 receptor blockers
strongly suggest that Ang II is a mediator of progressive
injury in DN [11, 34, 35].
Measurement of RAS components in plasma and ex-
perimental diabetes have generally shown suppression
of the system [11]. In early streptozotozin-induced (STZ)
diabetes, a model of type 1 diabetes, glomerular renin,
and ACE were elevated [36], while in another study, no
changes were observed [37]. Previous studies attempting
to measure intrarenal levels of Ang II have disclosed
inconsistent results [11]. In the present paper, by means
of an anti-Ang II antibody largely used [18], we have
noted elevated Ang II immunostaing in the kidneys of
DN, mainly in tubular and interstitial cells.
We have also found elevated ACE in tubular and
interstitial cells. ACE is up-regulated in proximal tubular
epithelium in some kidney diseases [33, 38, 39]. Tubular
cells are direct targets for high glucose levels present in
diabetes. Indeed, cultured tubular cells exposed to glu-
cose increased angiotensinogen gene expression and Ang II
secretion via a glucose-responsive element on the angio-
tensinogen promoter [40]. ACE over-expression was also
observed in renal fibroblast–like cells in the diabetic kid-
ney. In a model of fibrosing kidney, alterations of RAS
components have been described [41]. In renal intersti-
tial fibroblasts, all components of RAS are expressed
[41, 42] and are activated in response to Ang II, increas-
ing cell proliferation, fibrosis, and expression of angio-
tensinogen [43]. In patients with DN there was an ACE
switched expression from tubular epithelial cells to inter-
stitial cells, coinciding with an activation of myofibro-
blasts, suggesting an additional novel participation of
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Ang II as a mediator of tubulointerstitial injury. These
data, showing elevated renal Ang II production in the
diabetic kidney, could explain the observed beneficial
effects of RAS blockers in large clinical trials.
In DN patients, we have found significantly low AT1
receptor levels. A decrease in AT1 mRNA has also been
demonstrated in whole kidney biopsy samples from hu-
mans with type 2 diabetes [43]. In early STZ diabetes
the AT1 gene and protein is also down-regulated [44].
By contrast, in another experimental model of diabetes
an AT1, over-expression was described [37]. Although
AT1 is mostly down-regulated, there is an in vivo evi-
dence for enhanced sensitivity to Ang II in the diabetic
kidney. A potential explanation could be extrapolated
from studies in cultured vascular smooth muscle cells
(VSMC), which showed that high glucose levels aug-
mented Ang II responses such as cell proliferation, and
signaling sytems, including Janus kinase (JAK), signal
transducers and activators of transcription (STAT), and
NFB [31, 45]. Interestingly, we have observed that AT2
receptors are up-regulated in human DN. In our study,
no signal was found in glomeruli, as previously described
the in normal kidney [46]. In an experimental model of
early STZ, glomerular AT2 expression was down-regu-
lated [37], showing different responses in human and
experimental models of diabetes. AT2 receptor over-
expression, mainly in tubulointerstitium, has been de-
scribed in several models of renal injury, such as Ang II
infusion, sodium depletion, and renal ischemia reperfu-
sion [46, 47]. AT2 functions, including vasodilatation,
renal natriuresis, and inflammatory cell infiltration [15]
are well known, but the role of AT2 in DN remains to
be elucidated. The possibility that Ang II sensitivity ob-
served in diabetes could be mediated by AT2 is an impor-
tant point that needs to be addressed.
Inflammatory cells in the diabetic kidney contain ele-
vated levels of Ang II. Production of Ang II by immuno-
competent cells has also been described in animal models
of salt-sensitive hypertension [18]. Ang II can activate
immune cells, causing chemotaxis, proliferation, differ-
entiation, and production of chemokines [15]. Macro-
phages and lymphocytes, which are the main cell types in
the interstitial cell infiltration, are capable of generating
ROS and Ang II [18], and therefore Ang II generated
by inflammatory cells can contribute to the perpetuation
of the damage.
One potential mechanism that may explain NFB ac-
tivation found in human DN is the local Ang II pro-
duction. In vivo and in vitro Ang II activates NFB
and up-regulates NFB-related genes [15]. In glomerular
mesangial cells, endothelial cells, and VSMC, NFB acti-
vation occurs both via AT1 and AT2 [7, 48–50], while in
tubuloepithelial cells it only occurs through AT1 [7]. The
AT2/NFB pathway has also been demonstrated by spe-
cific AT2 agonists, and more recently in COS7 cells trans-
fected with AT2 receptors and PC12 cells, that only
express AT2 [50]. As the AT2 participates in the inflam-
matory response via the NFB pathway, and proinflam-
matory genes such as RANTES could be triggered via
AT2/NFB [15], it is tempting to speculate that the in-
flammatory cell infiltration observed in advanced DN
could be induced by this pathway. Excess glucose, to-
gether with elevated Ang II could contribute to the renal
damage. In VSMC, Ang II and glucose synergistically
increase NFB activation [45]. All of these data show
that Ang II, through the activation of the NFB pathway
and up-regulation of related genes, mainly in tubular
cells, could contribute to renal damage progression in
human DN.
CONCLUSION
Our study clearly shows that components of the intra-
renal RAS are selectively activated in the human diabetic
kidney. The simultaneous occurrence of interstitial cell
infiltration and renin-angiotensin activation suggests that
Ang II seems to be a key element in the renal inflamma-
tion in diabetic patients.
ACKNOWLEDGMENTS
This work was supported by research grants from Fondo Nacional
de Investigacio´n Cientı´fica y Tecnolo´gica, Chile (FONDECYT 1000433
and 1010373), Direccio´n de Investigacio´n, Universidad Austral, Val-
divia, Comunidad de Madrid (08.9/0002/2000), and Fondo de Investi-
gaciones Sanitarias (PI020513), Spain.
Reprint requests to Sergio Mezzano, M.D., Department of Ne-
phrology, School of Medicine, Universidad Austral, P.O. Box 8-D,
Valdivia, Chile.
E-mail: smezzano@uach.cl
REFERENCES
1. Barnes PJ, Karin M: Nuclear Factor-B. A pivotal transcription
factor in chronic inflammatory diseases. N Engl J Med 336:1066–
1071, 1997
2. May MJ, Ghosh S: Signal transduction through NF-B. Immunol
Today 19:80–88, 1998
3. Guijarro C, Egido J: Transcription factor B (NF-B) in renal
disease. Kidney Int 59:415–424, 2001
4. Wang Y, Rangan GK, Tay Y-C, et al: Induction of monocyte
chemoattractant protein-1 by albumin is mediated by nuclear factor
B in proximal tubule cells. J Am Soc Nephrol 10:1204–1213, 1999
5. Zoja C, Donadelli R, Colleoni S, et al: Protein overload stimu-
lates RANTES production by proximal tubular cells depending
on NF-B activation. Kidney Int 53:1608–1615, 1998
6. Ruiz-Ortega M, Bustos C, Herna´ndez-Presa MA, et al: Angio-
tensin II participates in mononuclear cell recruitment in experi-
mental immune complex nephritis through nuclear factor-kappa
B activation and monocyte chemoattractant protein-1 synthesis.
J Immunol 161:430–439, 1998
7. Ruiz-Ortega M, Lorenzo O, Rupe´rez M, et al: Systemic infusion
of angiotensin II into normal rats activates nuclear factor B and
AP-1 in the kidney. Role of AT1 and AT2 receptors. Am J Pathol
158:1743–1756, 2001
8. Go´mez-Garre D, Largo R, Tejera N, et al: Activation of nuclear
factor B in tubular epithelial cells of rats with intense proteinuria.
Role of angiotensin II and endothelin-1. Hypertension 37:1171–
1178, 2001
Mezzano et al: Inflammation and RAS in human diabetic nephropathyS-70
9. Mezzano S, Barrı´a M, Droguett MA, et al: Tubular NF-B and
AP-1 activation in human proteinuric renal disease. Kidney Int
60:1366–1377, 2001
10. Lopez-Franco O, Suzuki Y, Sanjuan G, et al: Nuclear factor-
kappa B inhibitors as potential novel anti-inflammatory agents for
the treatment of immune glomerulonephritis. Am J Pathol 161:
1497–1505, 2002
11. Burns KD: Angiotensin II and its receptors in the diabetic kidney.
Am J Kidney Dis 36:449–463, 2000
12. Lewis EJ, Hunsicker LG, Clarke WR, et al: For the Collaborative
Study Group: Renoprotective effect of the angiotensin-receptor
antagonist irbesartan in patients with nephropathy due to type 2
diabetes. N Engl J Med 345:851–860, 2001
13. Brenner BM, Cooper ME, de Zeeuw D, et al: RENAAL Study
Investigators: Effects of losartan on renal and cardiovascular out-
comes in patients with type 2 diabetes and nephropathy. N Engl
J Med 345:861–869, 2001
14. Parving HH, Lehnert H, Brochner-Mortensen J, et al: For the
Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria
Study Group: The effect of irbesartan on the development of dia-
betic nephropathy in patients with type 2 diabetes. N Engl J Med
345:870–878, 2001
15. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al: Renin-angiotensin
system and renal damage: Emerging data on angiotensin II as a
proinflammatory mediator. Contrib Nephrol 135:123–137, 2001
16. Ruiz-Ortega M, Rupe´rez M, Lorenzo O, et al: Angiotensin II
regulates the synthesis of proinflammatory cytokines and chemo-
kines in the kidney. Kidney Int 82:12–22, 2002
17. Mezzano S, Droguett MA, Burgos ME, et al: Overexpression
of chemokines, fibrogenic cytokines, and myofibroblasts in human
membranous nephropathy. Kidney Int 57:147–158, 2000
18. Rodrı´guez-Iturbe B, Pons H, Herrera-Acosta J, Johnson R:
Role of immunocompetent cells in nonimmune renal diseases.
Kidney Int 59:1626–1640, 2001
19. Lombardi DM, Viswanathan M, Vı´o CP, et al: Renal and vascular
injury induced by exogenous angiotensin II is AT1 receptor-depen-
dent. Nephron 87:66–74, 2001
20. Iwamoto M, Mizuiri S, Tanimoto H, et al: Nuclear factor-B
activation in streptozotocin induced diabetic rats kidneys. J Am
Soc Nephrol 12(Suppl):838, 2001
21. Morcos M, Sayed AA, Bierhaus A, et al: Activation of tubular
epithelial cells in diabetic nephropathy. Diabetes 51:3532–3544, 2002
22. Lal M, Brismar H, Eklof AC, Aperia A: Role of oxidative stress
in advanced glycation end product–induced mesangial cell activa-
tion. Kidney Int 61:2006–2014, 2002
23. Hofmann MA, Schiekofer S, Kanitz M, et al: Insufficient glycemic
control increases nuclear factor-kapa B binding activity in periph-
eral blood mononuclear cells isolated from patients with type 1
diabetes. Diabetes Care 21:1310–1316, 1998
24. Hofmann MA, Schiekofer S, Isermann B, et al: Peripheral blood
mononuclear cells isolated from patients with diabetic nephropathy
show increased activation of the oxidative-stress sensitive tran-
scription factor NF-kappa B. Diabetologia 42:222–232, 1999
25. Mohamed AK, Bierhaus A, Schiekofer S, et al: The role of oxida-
tive stress and NF-kappa B activation in late diabetic complications.
Biofactors 10:157–167, 1999
26. Kato S, Luyckx VA, Ots M, et al: Renin-angiotensin blockade
lowers MCP-1 expression in diabetic rats. Kidney Int 56:1037–
1048, 1999
27. Wada T, Furuichi K, Sakai N, et al: Up-regulation of monocyte
chemoattractant protein-1 in tubulointerstitial lesions of human
diabetic nephropathy. Kidney Int 58:1492–1499, 2000
28. Banba N, Nakamura T, Matsumura M, et al: Possible relationship
of monocyte chemoattractant protein-1 with diabetic nephropathy.
Kidney Int 58:684–690, 2000
29. Remuzzi G, Ruggenenti P, Begnini A: Understanding the nature
of renal disease progression. Kidney Int 51:2–15, 1997
30. Abbate M, Zoja C, Corna D, et al: In progressive nephropathies,
overload of tubular cells with filtered proteins translates glomerular
permeability dysfunction into cellular signals of interstitial in-
flammation. J Am Soc Nephrol 9:1213–1224, 1998
31. Natarajan R, Scott S, Bai W, et al: Angiotensin II signaling in
vascular smooth muscle cells under high glucose conditions. Hyper-
tens 33:378–384, 1999
32. Morigi M, Macconi D, Zoja C, et al: Protein overload-induced
NF-B activation in proximal tubular cells requires H2O2 through
a PKC-dependent pathway. J Am Soc Nephrol 13:1179–1189, 2002
33. Largo R, Go´mez-Garre D, Soto K, et al: Angiotensin-converting
enzyme is upregulated in the proximal tubules of rats with intense
proteinuria. Hypertens 33:732–739, 1999
34. Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II
in diabetic nephropathy. Kidney Int 58:s93–s98, 2000
35. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibi-
tion: From ACEI to angiotensin II antagonists. Kidney Int 57:1803–
1817, 2000
36. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin
system in diabetes: Functional, immunohistochemical, and molecu-
lar biological correlations. Am J Physiol 265:F477–F486, 1993
37. Wehbi GJ, Zimpelmann J, Carey RM, et al: Early streptozotocin-
diabetes mellitus downregulates rat kidney AT2 receptors. Am J
Physiol Renal Physiol 280:F254–F265, 2001
38. Pimentel JL, Jr, Montero A, Wang S, et al: Sequential changes
in renal expression of renin-angiotensin system genes in acute
unilateral ureteral obstruction. Kidney Int 48:1247–1253, 1995
39. Ruiz-Ortega M, Gonza´lez S, Seron D, et al: ACE inhibition
reduces proteinuria, glomerular lesions and extracellular matrix
production in a normotensive rat model of immune complex ne-
phritis. Kidney Int 48:1778–1791, 1995
40. Zhang SL, Chen X, Wei CC, et al: Insulin inhibits dexamethasone
effect on angiotensinogen gene expression and induction of hyper-
trophy in rat kidney proximal tubular cells in high glucose. Endocri-
nology 143:4627–4635, 2002
41. Okada H, Inoue T, Kanno Y, et al: Interstitial fibroblast-like cells
express renin-angiotensin system components in a fibrosing murine
kidney. Am J Pathol 160:765–772, 2002
42. Ruiz-Ortega M, Egido J: Angiotensin II modulates cell growth-
related events and synthesis of matrix proteins in renal interstitial
fibroblasts. Kidney Int 52:1497–1510, 1997
43. Wagner J, Gehlen F, Ciechanowicz A, Ritz E: Angiotensin II
receptor type 1 gene expression in human glomerulonephritis and
diabetes mellitus. J Am Soc Nephrol 10:545–551, 1999
44. Cheng HF, Burns KD, Harris RC: Reduced proximal tubule
angiotensin II receptor expression in streptozotocin-induced diabe-
tes mellitus. Kidney Int 46:1603–1610, 1994
45. Fujita N, Furukawa Y, Du J, et al: Hyperglycemia enhances
VSMC proliferation with NF-kappaB activation by angiotensin II
and E2F–1 augmentation by growth factors. Mol Cell Endocrinol
28:75–84, 2002
46. Ozono R, Wang ZQ, Moore AF, et al: Expression of the subtype
2 angiotensin (AT2) receptor protein in rat kidney. Hypertens
30:1238–1246, 1997
47. Kontogiannis J, Burns KD: Role of AT1 angiotensin II receptors
in renal ischemic injury. Am J Physiol 274:F79–90, 1998
48. Ruiz-Ortega M, Lorenzo O, Rupe´rez M, et al: Angiotensin II
activates nuclear transcription factor B through AT1 and AT2 in
vascular smooth muscle cells. Molecular mechanisms. Circ Res 86:
1266–1272, 2000
49. Lorenzo O, Ruiz-Ortega M, Susuki Y, et al: Angiotensin II
activates nuclear transcription factor-B in cultured mesangial cells
mainly via AT2 receptors: Studies with AT1 receptor-knockout
mice. J Am Soc Nephrol 13:1162–1171, 2002
50. Wolf G, Wenzel U, Burns KD, et al: Angiotensin II activates
nuclear transcription factor-kappa B through AT1 and AT2 recep-
tors. Kidney Int 61:1986–1995, 2002
